CD86 and colorectal cancer: Furthermore, a preclinical study in a human HER2-expressing murine colorectal cancer model reported an increase in the levels of tumor-infiltrating DCs and CD86+ and CD8+ T cells induced by T-DXd treatment, suggesting that this treatment may enhance antitumor immunity and induce immunogenic cell death (12).